Gastrointestinal (GI) cancers are one of the leading causes of cancer deaths worldwide, accounting for nearly 780,000 deaths a year. There is a clear need to better understand the pathogenesis and pathophysiology of GI cancers, identify and validate new molecular determinants for GI cancer management, and develop new therapeutic options for patients with GI malignancies. Metabolites are proven to play an increasingly versatile role in biological interactions, not just as substrates and products of enzyme driven reactions but also as crucial system regulators. Cancer cells can repurpose these systems to drive unwanted proliferation, survival and growth in cancers.
The last decade has started to highlight the role the metabolome plays in GI malignancies. The metabolome is the global collection of all low molecular weight metabolites that are produced by cells during metabolism, and provides a direct functional readout of cellular activity and physiological status. Metabolomics is a high-throughput analytical strategy to qualify or quantify as many metabolites as possible in the metabolomes and recent analysis of this field has yielded useful results in the treatment and management of GI cancers. Our understanding of metabolome in GI malignancies can be employed to identify biomarkers for prediction, diagnosis, and prognosis.. Therefore, expanding the knowledge in base of metabolome will have a tremendous impact on on diagnosis, management and treatment of GI cancers.
This Research Topic will focus on metabolome research in GI malignancies. Original research and Review articles should present new data from clinical or basic research as well as analyze or discuss, with innovative and critical observations, previous research. Important topics to discuss include but are not limited to:
1. Insights in metabolomics and GI cancers.
2. Metabolomic signature associated with GI cancers.
3. Potential future metabolomic studies for GI malignancies.
4. The interactions between metabolites and the GI tumor microenvironment.
5. Current or potential characteristics of GI metabolome.
6. Metabolomics to develop predictive models or biomarkers of GI cancer.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Gastrointestinal (GI) cancers are one of the leading causes of cancer deaths worldwide, accounting for nearly 780,000 deaths a year. There is a clear need to better understand the pathogenesis and pathophysiology of GI cancers, identify and validate new molecular determinants for GI cancer management, and develop new therapeutic options for patients with GI malignancies. Metabolites are proven to play an increasingly versatile role in biological interactions, not just as substrates and products of enzyme driven reactions but also as crucial system regulators. Cancer cells can repurpose these systems to drive unwanted proliferation, survival and growth in cancers.
The last decade has started to highlight the role the metabolome plays in GI malignancies. The metabolome is the global collection of all low molecular weight metabolites that are produced by cells during metabolism, and provides a direct functional readout of cellular activity and physiological status. Metabolomics is a high-throughput analytical strategy to qualify or quantify as many metabolites as possible in the metabolomes and recent analysis of this field has yielded useful results in the treatment and management of GI cancers. Our understanding of metabolome in GI malignancies can be employed to identify biomarkers for prediction, diagnosis, and prognosis.. Therefore, expanding the knowledge in base of metabolome will have a tremendous impact on on diagnosis, management and treatment of GI cancers.
This Research Topic will focus on metabolome research in GI malignancies. Original research and Review articles should present new data from clinical or basic research as well as analyze or discuss, with innovative and critical observations, previous research. Important topics to discuss include but are not limited to:
1. Insights in metabolomics and GI cancers.
2. Metabolomic signature associated with GI cancers.
3. Potential future metabolomic studies for GI malignancies.
4. The interactions between metabolites and the GI tumor microenvironment.
5. Current or potential characteristics of GI metabolome.
6. Metabolomics to develop predictive models or biomarkers of GI cancer.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
